Understanding and Applying ICH Q3A and Q3B for Control of Impurities in Drug Substances and Drug Products
By attending this webinar the participiants should be able to Understand regulatory expectations regarding impurities, degradants and potential genotoxic impurities in pharmaceuticals and also Understand ICH Q3A and Q3B.
December 18, 2020
10:00 AM PST | 01:00 PM EST
More Trainings by this Expert
Product Id : 503443
Live: One Dial-in One Attendee
Corporate Live: Any number of participants
Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
This course is designed to provide participants with an understanding of the regulatory expectations for controlling impurities and degradants (including DNA reactive/potential genotoxic impurities) in drug substances and drug products. There will be ample opportunity to discuss questions and challenges from the participants.
Why should you Attend:
Upon completion of this course the learner should be able to:
Areas Covered in the Session:
- Understand regulatory expectations regarding impurities, degradants and potential genotoxic impurities in pharmaceuticals
- Understand what specifications will conform to regulatory expectations
- Develop an process for reporting impurities and addressing OOS situations
Who Will Benefit:
- Landscape of impurities requiring control in pharmaceutical products
- General impurities: elemental impurities, residual solvents, microbiological
- Drug-related impurities process impurities, degradants, potentially genotoxic impurities
- Process Impurities
- Understanding ICH Q3A
- Where impurities originate
- How impurities are characterized
- How specifications are developed
- How impurities should be reported
- Understanding ICH Q3B
- Where degradants originate
- How degradants are characterized
- Potential genotoxic impurities
- How specifications are developed
- How degradants should be reported
- Questions and discussion
- Quality Engineers
- Manufacturing Engineers
- Internal Auditors
- Quality Specialists
- Quality Associates
- Operations and Manufacturing Managers
- Process Engineers
Greg Martin is President of Complectors Consulting (www.complectors.com) which provides consulting and training in the area of Pharmaceutical Analytical Chemistry. He has over 25 years experience in the pharmaceutical industry and was Director of Pharmaceutical Analytical Chemistry (R&D) for a major Pharma company for a number of years.
In addition, he has volunteered for the USP for over 10 years, and currently serves on the General Chapters - Chemical Analysis Expert Committee, and serves on Expert Panels on Validation and Verification, Residual Solvents and Use of Enzymes for Dissolution Testing of Gelatin Capsules.
He has particular interest in QbD/Lean approaches to dissolution testing, impurity methods, method lifecycle (development/validation/transfer) and instrument qualification, and is passionate about using good science and sound logic to achieve high quality results, consistent with cGMPs, while minimizing resources.
Mr. Martin is author of several papers in the areas of dissolution and analytical method validation, and is past chair of the AAPS In Vitro Release and Dissolution Testing Focus Group.